CandlesenseCandlesense
News/Companies/MNPR

MNPR News

Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025

MNPR

WILMETTE, Ill., Nov. 09, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, is presenting new data and analyses today from the Phase 2 ALXN1840-WD-204 copper balance study at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2025, taking place in Washington, D.C., from November 7-11, 2025.

November 9, 2025
Read more →

Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments

MNPR

WILMETTE, Ill., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced second quarter 2025 financial results and recent developments.

August 12, 2025Earnings
Read more →

Monopar And EDNOC Announce Expanded Access Program For MNPR-101-Zr And MNPR-101-Lu In Advanced Cancers

MNPR

June 11, 2025
Read more →

Monopar Therapeutics Q1 EPS $(0.38) Beats $(0.68) Estimate

MNPR

May 13, 2025
Read more →

Monopar Presents ALXN1840 Late-Breaker Data At EASL 2025, Highlighting Long-Term Efficacy And Safety In Wilson Disease Across Three Clinical Trials

MNPR

May 7, 2025
Read more →

HC Wainwright & Co. Reiterates Buy on Monopar Therapeutics, Maintains $40 Price Target

MNPR

April 1, 2025
Read more →

Monopar Therapeutics Q4 2024 GAAP EPS $(2.23) Misses $(0.42) Estimate

MNPR

March 31, 2025
Read more →

Monopar Therapeutics Q4 EPS $(2.23) Down From $(0.60) YoY

MNPR

March 31, 2025
Read more →

Piper Sandler Assumes Monopar Therapeutics at Overweight, Announces Price Target of $76

MNPR

March 19, 2025
Read more →

Piper Sandler Initiates Coverage On Monopar Therapeutics with Overweight Rating, Announces Price Target of $72

MNPR

January 10, 2025
Read more →

Monopar Therapeutics Prices $40M Public Offering Of Common Stock Of 798,655 Shares At $23.79/Share; Concurrent Private Placement Of Pre-Funded Warrants To Purchase 882,761 Shares At $23.789/Pre-Funded Warrant

MNPR

December 20, 2024
Read more →